| Date | Title | | | 11/11/09 | Curis to Present at Lazard Capital Markets 6th Annual Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 11, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation targeted small molecule drug candidates for
cancer treatment, today announced that the Company will be presenting at
the Lazard Capital Markets 6th Annual Healthcare Conference at 3:45 p.m.
EST on November 18, 2009, in New York City.
Dan Passeri, Curis’ President and Chief Executive Officer, will... |
|  | | 11/03/09 | Curis to Present at Merriman Curhan Ford's Investor Summit 2009| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 3, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation targeted small molecule drug candidates for
cancer treatment, today announced that the Company will be presenting at
Merriman Curhan Ford’s Investor Summit at 9:00 a.m. EST on November 10,
2009, in New York City.
Dan Passeri, Curis’ President and Chief Executive Officer, will provide
... |
| | | 10/29/09 | Curis Reports Third Quarter 2009 Financial Results|
-- Conference call to be held today at 9:00 am EDT --
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 29, 2009--
Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop
proprietary targeted medicines for cancer treatment, today reported its
financial results for the third quarter ended September 30, 2009.
“The third quarter of 2009 was significant for Curis, as we entered into
a license agreement with Debiopharm for... |
| | | 10/27/09 | Curis to Present at the Oppenheimer 20th Annual Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 27, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation targeted small molecule drug candidates for
cancer treatment, today announced that the Company will be presenting at
the Oppenheimer 20th Annual Healthcare Conference at 3:55
p.m. EST on November 3, 2009, at the Waldorf Astoria in New York City.
Dan Passeri, Curis’ President and Chief Executive O... |
| | | 10/22/09 | Curis to Release Third Quarter 2009 Financial Results and Hold Conference Call on October 29, 2009| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 22, 2009--
Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop
proprietary targeted medicines for cancer treatment, today announced
that the Company will release its third quarter financial results on
Thursday, October 29, 2009 before the market opens. The Company will
also hold a conference call on the same day at 9:00 A.M. Eastern time to
discuss: (i) its Hedgehog Pathway Inhibitor progra... |
| | | 10/21/09 | Curis to Present at the 8th Annual BIO Investor Forum| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 21, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation targeted small molecule drug candidates for
cancer treatment, today announced that the Company will be presenting at
the 8th Annual BIO Investor Forum at 4:30 p.m. PDT (7:30 p.m.
EDT) on October 28, 2009, at the Palace Hotel in San Francisco,
California.
Dan Passeri, Curis’ President and C... |
| | | 09/22/09 | Curis to Present at Maxim Group Growth Conference 2009| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 22, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation targeted small molecule drug candidates for
cancer treatment, today announced that the Company will be presenting at
the Maxim Group Growth Conference 2009 at 3:30 p.m. EDT on September 29,
2009, at the Grand Hyatt Hotel in New York City.
Dan Passeri, Curis’ President and Chief Executive Officer,... |
| | | 09/03/09 | Curis Announces GDC-0449 Phase I Clinical Data Published in New England Journal of Medicine|
Phase I Data in 33 Patients Demonstrates Molecule’s Potential as
Treatment for Locally Advanced and Metastatic Basal Cell Carcinoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 3, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on
developing proprietary targeted medicines for cancer treatment, today
announced that two publications describing clinical data generated with
GDC-0449 were published in the current edition o... |
| | | 09/02/09 | Curis to Present at the Rodman & Renshaw 11th Annual Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 2, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation targeted small molecule drug candidates for
cancer treatment, today announced that the Company will be presenting at
the Rodman & Renshaw 11th Annual Healthcare Conference at 12:05 p.m. EDT
on September 9, 2009, at the New York Palace Hotel in New York City.
Dan Passeri, Curis’ President and C... |
| | | 08/06/09 | Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305| CAMBRIDGE, Mass. & LAUSANNE, Switzerland, Aug 06, 2009 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on
developing proprietary targeted medicines for cancer treatment and
Debiopharm Group (Debiopharm), a group of companies with a focus on the
development of prescription drugs that target unmet medical needs today
announced that they have entered into a worldwide, exclusive license
agreement for Curis' Heat Shock Protein ... |
| | | 07/30/09 | Curis Reports Second Quarter 2009 Financial Results and Provides Pipeline Update|
.bwcellpaddingbottom1 {padding-bottom: 2.0px; font: 100% arial; }
.bwcellpaddingbottom3 {padding-bottom: 4.0px; font: 100% arial; }
.bwcellpaddingleft0 {padding-left: 0.0px; font: 100% arial; }
.bwcellpaddingleft1 {padding-left: 5.0px; font: 100% arial; }
.bwcellpaddingleft2 {padding-left: 10.0px; font: 100% arial; }
.bwcellpaddingleft4 {padding-left: 20.0px; font: 100% arial; }
.bwcellpaddingleft5 {padding-left: 25.0px; font: 100% arial; }
.bwcellpaddingleft6 {padding-l... |
| | | 07/23/09 | Curis to Release Second Quarter 2009 Financial Results and Hold Conference Call on July 30, 2009| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 23, 2009--
Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop
proprietary targeted medicines for cancer treatment, today announced
that the Company will release its second quarter financial results on
Thursday, July 30, 2009 before the market opens. The Company will also
hold a conference call on the same day at 9:00 A.M. Eastern time to
discuss: (i) its Hedgehog pathway inhibitor program ... |
| | | 06/29/09 | Curis Added to Russell 3000(R) and Russell 2000(R) Indexes| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 29, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on
developing proprietary targeted medicines for cancer treatment, today
announced that it was added to the Russell 3000® and
Russell 2000® Indexes when Russell Investment Group
reconstituted its family of U.S. indexes after stock market close on
June 26, 2009.
The Russell family of U.S. indexes is designed to be a comprehe... |
| | | 06/17/09 | Curis Announces Issuance of U.S. Patent Covering CUDC-101 Composition of Matter for Novel HDAC/EGFR/Her2 Inhibitor| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 17, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on
developing proprietary targeted medicines for cancer treatment, today
announced the issuance of U.S. Patent Number 7,547,781, entitled
“Quinazoline Based EGFR Inhibitors Containing a Zinc Binding Moiety.”
The patent covers a genus of compounds that includes CUDC-101, Curis’
HDAC/EGFR/Her2 inhibitor, which is currently in a Phase I clin... |
| | | 06/10/09 | Curis Publishes Preclinical Data for Heat Shock Protein 90 Molecule CUDC-305 in Clinical Cancer Research| - CUDC-305, lead development candidate from novel small molecule chemical class of Heat Shock Protein (HSP) 90 inhibitors, demonstrates potent anti-cancer activity in pre-clinical cancer models and possesses favorable pharmacological properties -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 10, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on
developing proprietary targeted medicines for cancer treatment, today
announced that preclinical data related ... |
| | | 06/04/09 | Curis to Present at the 8th Annual Needham Life Sciences Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 4, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation targeted small molecule drug candidates for
cancer treatment, today announced that the Company will be presenting at
the 8th Annual Needham Life Sciences Conference at 1:00 p.m. EDT on June
10, 2009, at the New York Palace Hotel in New York City.
Dan Passeri, Curis’ President and Chief Executive Officer, ... |
| | | 05/13/09 | Curis to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 13, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation targeted small molecule drug candidates for
cancer treatment, today announced that the Company will be presenting at
the Leerink Swann Novel Cancer Therapeutics Roundtable Conference at
1:30 p.m. EDT on May 20, 2009, at the Roosevelt Hotel in New York City.
Dan Passeri, Curis’ President and Chief Executi... |
| | | 05/05/09 | Curis Reports First Quarter 2009 Financial Results| -- Conference Call to be Held Today at 9:00 am EDT --
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 5, 2009--
Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop
proprietary targeted medicines for cancer treatment, today reported its
financial results for the quarter ended March 31, 2009.
“One of the highlights of the first quarter was the initiation by our
collaborator Genentech of a pivotal Phase II trial of a first-in-class
... |
| | | 04/28/09 | Curis to Release First Quarter 2009 Financial Results and Hold Conference Call on May 5, 2009| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 28, 2009--
Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop
proprietary targeted medicines for cancer treatment, today announced
that the Company will release its first quarter financial results on
Tuesday, May 5, 2009 before the market opens. The Company will also hold
a conference call on the same day at 9:00 A.M. Eastern time to discuss:
(i) its Hedgehog pathway inhibitor program unde... |
| | | 04/27/09 | Curis Presents Preclinical Data for CU-903 at Keystone Symposia Event "PI3 Kinase Signaling in Disease"| - Novel small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) demonstrates potent anti-cancer activity in pre-clinical cancer models -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 27, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on
developing proprietary targeted medicines for cancer treatment, today
announced that an oral presentation entitled, "A Single Small Molecule
That Inhibits Histone Deacetylas... |
| | | 04/22/09 | Curis Presents CUDC-305 Preclinical Data at the AACR 100th Annual Meeting 2009| Orally available Hsp90 inhibitor demonstrates potent anti-cancer activity across solid and hematological preclinical cancer models
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 22, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop proprietary targeted medicines for cancer treatment, today
announced data provided in two presentations on the Company’s Hsp90
development candidate, CUDC-305. These presentations were given by Curis
scie... |
| | | 04/09/09 | Curis Announces Presentations at American Association for Cancer Research Annual Meeting 2009| CAMBRIDGE, Mass., Apr 09, 2009 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation proprietary targeted medicines for cancer
treatment, today announced that it will present data on one of its
proprietary oncology programs at the upcoming American Association for
Cancer Research (AACR) 100th Annual Meeting to be held in
Denver, CO at the Colorado Convention Center on April 18-22.
Curis scientists wil... |
| | | 03/11/09 | Curis to Present at the Cowen and Company 29th Annual Health Care Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 11, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation targeted small molecule drug candidates for
cancer treatment, today announced that the Company will be presenting at
the Cowen and Company 29th Annual Health Care Conference, at
4:40 p.m. EDT on March 17, 2009, at the Marriott Copley Place Hotel in
Boston, Massachusetts.
Dan Passeri, Curis’ Presid... |
| | | 03/04/09 | Curis to Present at the Barclays Capital Global Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 4, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation targeted small molecule drug candidates for
cancer treatment, today announced that the Company will be presenting at
the Barclays Capital Global Healthcare Conference, at 3:15 p.m. EDT on
March 11, 2009, at the Loews Hotel in Miami, Florida.
Dan Passeri, Curis’ President and Chief Executive Officer, will ... |
| | | 02/12/09 | Curis Announces Genentech's Initiation of Pivotal Phase II Trial of GDC-0449 in Advanced Basal Cell Carcinoma| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 12, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation proprietary targeted medicines for cancer
treatment, today announced that its collaborator Genentech treated the
first patient in a pivotal Phase II clinical trial of GDC-0449, an
orally-administered small molecule Hedgehog Pathway Inhibitor, as a
single-agent therapy for patients with metastatic or locally adva... |
| | | 02/10/09 | Curis Reports Fourth Quarter and Year-End 2008 Financial Results| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 10, 2009--
Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop
next generation proprietary targeted medicines for cancer treatment,
today reported its financial results for the fourth quarter and fiscal
year ended December 31, 2008.
“The fourth quarter and early 2009 have been important periods for
Curis, as our collaborator Genentech initiated a Phase II trial of
GDC... |
| | | 02/09/09 | Curis Announces Collaborative Agreement between Genentech and National Cancer Institute on GDC-0449| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 9, 2009--
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation proprietary targeted medicines for cancer
treatment, today announced that Curis’ collaborator Genentech, Inc. and
the National Cancer Institute’s (NCI) Division of Cancer Treatment and
Diagnosis (DCTD) are planning to enter into a Cooperative Research and
Development Agreement (CRADA) which will allow... |
| | | 02/04/09 | Curis to Present at the 11th Annual BIO CEO Investor Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation targeted small molecule drug candidates for
cancer treatment, today announced that the Company will be presenting at
the 11th Annual BIO CEO Investor Conference, at 11:00 a.m.
EST on February 10, 2009, at the Waldorf Astoria Hotel in New York, New
York.
Dan Passeri, Curis’ President and Chief Executive Officer, ... |
| | | 02/03/09 | Curis to Release Fourth Quarter and Year-end 2008 Financial Results and Hold Conference Call on February 10, 2009| CAMBRIDGE, Mass., Feb 03, 2009 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop proprietary targeted medicines for cancer treatment, today
announced that the Company will release its fourth quarter financial
results on Tuesday, February 10, 2009 before the market opens. The
Company will also hold a conference call on the same day at 9:00 A.M.
Eastern time to discuss: (i) its Hedgehog pathway inhibitor program
... |
| | | 01/15/09 | Curis Announces Genentech's Expected Initiation of Pivotal Phase II Trial in Advanced Basal Cell Carcinoma with Hedgehog Pathway Inhibitor| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 15, 2009--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation proprietary targeted medicines for cancer
treatment, today announced that its collaborator Genentech has indicated
that it expects to initiate in January 2009 a pivotal Phase II clinical
trial of GDC-0449, an orally-administered small molecule Hedgehog
Pathway Inhibitor, as a single-agent therapy for patients with
... |
| |
|
